Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.

Conditions: Diabetes Mellitus, Type 2; Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; CKD; Proteinuria Interventions: Drug: Dapagliflozin 10mg Tab; Drug: Placebo; Device: Withings BPM Connect; Device: Withings Body+; Diagnostic Test: Hem-Col Capillary Blood Collection Device; Device: MEMS (Medication Electronic Monitoring System) Cap; Behavioral: Questionnaire: participants ' perspectives toward remote data collection Sponsors: University Medical Center Groningen; AstraZeneca Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials